menu
    • menu
    [{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Discovery Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Discovery Therapeutics

    Menu

    Discovery Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Discovery Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Discovery Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Epidermal Growth Factor

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Discovery Therapeutics Receives FDA Approval To Initiate Phase 3 Trial

                            Details : rhEGF (recombinant human epidermal growth factor) is a 53 amino acid polypeptide being evaluated for treating complex refractory neuropathic, ischemic, and neuroischemic diabetic foot ulcers.

                            Brand Name : rhEGF

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Recombinant Human Epidermal Growth Factor

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth